Download PDF

Price: $0
No charge, funded by The Conference Board of Canada and/or the research sponsor

Pharmacare in Canada: Financial Implications of Alternative Models for Public and Private Payers

The Conference Board of Canada, 16 pages, October 3, 2018
Briefing by ,
(You must be signed in and entitled to rate this report)
This briefing estimates the change in drug reimbursement of three alternative scenarios, assuming a national pharmacare plan is introduced in 2020.

Document Highlights

Pharmacare in Canada: Financial Implications of Alternative Models for Public and Private Payers estimates the change in drug reimbursement of three alternative pharmacare scenarios, assuming a national pharmacare plan is introduced in 2020: 1) Public Plan as First Payer, 2) The Quebec Program, and 3) The British Columbia Program.

The burden of drug costs could shift considerably, regardless of the model. In scenario 1, the burden is shifted almost entirely to public plans, with the costs being borne by the federal government or by the individual provincial/territorial governments. In scenarios 2 and 3, there is also a shift to the public plans, but to a lesser extent than in scenario 1. Findings of this research are meant to help inform discussions on the implementation of national pharmacare.

Download PDF

Price: $0
No charge, funded by The Conference Board of Canada and/or the research sponsor